[Form 4] Lexaria Bioscience Corp. Warrant Insider Trading Activity

Rhea-AI Filing Summary

On 07/29/2025, Lexaria Bioscience Corp. (LEXX) Secretary Vanessa Carle filed a Form 4 disclosing her first reported open-market purchase of the company’s common stock. She bought 750 shares at $0.91 each, bringing her direct common-share ownership to 750 shares (≈ US$680 at the transaction price). Carle also holds 75,000 stock options with exercise prices ranging from $1.04 to $3.00 and expirations between 2026-2030. No option activity was reported; the filing simply restates her existing derivative positions. The dollar value and share count involved are modest and unlikely to be financially material, but the purchase may signal incremental insider confidence.

Positive

• Officer open-market purchase may be perceived as confidence signal, albeit modest.

Negative

• Transaction size is immaterial—only 750 shares (~US$680), limiting market impact.

Insights

Equity Analyst

TL;DR: Very small insider buy; symbolic confidence, financially immaterial.

Carle’s US$680 purchase of 750 LEXX shares is nominal relative to float and daily volume, therefore unlikely to move valuation models. However, any insider buying—especially from officers—can improve market sentiment for micro-caps. Her 75k in-the-money options (lowest strike $1.04) indicate long-term alignment, but the majority remain out-of-the-money at higher strikes. Overall impact is neutral with a slight positive tone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Carle Vanessa

(Last) (First) (Middle)

100 - 740 MCCURDY ROAD

(Street)

KELOWNA A1 V1X 2P7

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexaria Bioscience Corp. [ LEXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Secretary

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
common shares	07/29/2025		P		750	A	$0.91	750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$3							04/26/2021	04/26/2026	Common Shares	12,500		12,500	D
Stock Options	$3							06/08/2021	06/08/2026	Common Shares	5,000		17,500	D
Stock Options	$3							09/01/2021	09/01/2026	Common Shares	10,000		27,500	D
Stock Options	$2.91							08/29/2022	08/29/2027	Common Shares	12,500		40,000	D
Stock Options	$1.15							10/26/2023	10/26/2028	Common Shares	10,000		50,000	D
Stock Options	$2.36							04/26/2024	04/26/2029	Common Shares	10,000		60,000	D
Stock Options	$1.04							05/15/2025	05/15/2030	Common Shares	15,000		75,000	D

Explanation of Responses:

	/Vanessa Carle/	07/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Lexaria (LEXX) shares did Vanessa Carle buy?

She purchased 750 common shares on 07/29/2025.

At what price were the shares acquired?

The shares were bought at $0.91 per share.

What is Vanessa Carle’s total direct share ownership after the trade?

Her direct ownership is 750 common shares.

How many stock options does the insider hold?

Carle holds 75,000 options with strikes between $1.04 and $3.00 expiring 2026-2030.

Does this Form 4 indicate any option exercises or sales?

No. The filing lists existing option positions; no derivative transactions occurred.